Zhong Jin Zai Xian·2025-04-25 03:41Core Insights - Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor, Engokshin® (generic name: Ponatinib tablets), has been launched on JD Health, providing new treatment options for patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1][2] - Engokshin® received approval for domestic market launch in September 2024, showcasing strong broad-spectrum specificity, particularly effective against the T315I mutant Bcr-Abl kinase, addressing resistance issues common with earlier generation inhibitors [1][2] Product Efficacy and Safety - In clinical trials, Engokshin® demonstrated remarkable efficacy, with 64% of T315I mutant patients achieving ≤1% BCR-ABL1IS within 48 months, and a 4-year survival rate of 88% in the 45 mg dosage group [2] - Most adverse events related to Ponatinib treatment were grade 1 or 2, manageable through dose adjustments, indicating a controllable safety profile [2] Market Accessibility and Patient Support - JD Health aims to enhance the accessibility of Engokshin® through its comprehensive supply chain and healthcare service capabilities, ensuring safe delivery under controlled temperature conditions [1][2] - The collaboration between JD Health and Otsuka Pharmaceutical includes disease education and patient service initiatives, aimed at improving public health literacy regarding blood cancers [2]